Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?

Eli Lilly's oral GLP-1 candidate, Orforglipron, delivered Phase III ATTAIN-1 study results showing 12.4% weight loss, which fell short of investor expectations for 13-15% comparable to Wegovy and exhibited a high 24.4% discontinuation rate. This perceived setback has tempered market expectations for the drug's potential, contributing to LLY's 7.6% year-to-date stock decline. However, Lilly maintains a robust obesity pipeline, including other late-stage candidates like retatrutide, amidst intensifying competition in the rapidly expanding $100 billion obesity market by 2030, where rivals like Novo Nordisk, Amgen, and Viking Therapeutics are also developing advanced oral and injectable GLP-1 therapies.

Analysis

Eli Lilly's (LLY) position in the lucrative obesity market faces a notable challenge following disappointing Phase III results for its oral candidate, orforglipron. The ATTAIN-1 study showed a 12.4% weight loss, which fell short of investor expectations benchmarked against the 13-15% efficacy of Novo Nordisk's injectable Wegovy. Compounding this, a high patient discontinuation rate of 24.4% in the highest dose arm raises significant concerns about the drug's tolerability and commercial viability. This setback has directly impacted investor sentiment, contributing to LLY's 7.6% year-to-date stock decline against a flat industry trend. Despite this, Lilly's growth story is not solely dependent on orforglipron; the company possesses a deep pipeline including another late-stage candidate, retatrutide, and has four more orforglipron studies reporting over the next five months. The competitive landscape for the projected $100 billion obesity market is intensifying, with Novo Nordisk's oral Wegovy awaiting an FDA decision in Q4 and Amgen advancing its monthly injectable, MariTide, into Phase III trials. While LLY's stock trades at a premium forward P/E of 25.29, above the industry's 14.64, earnings estimates for 2025 and 2026 have been revised upwards, indicating underlying confidence in its existing blockbuster GLP-1 therapies, Mounjaro and Zepbound.

Key Decisions for Investors

• Investors should closely monitor upcoming data from Lilly's broader obesity pipeline, particularly the remaining orforglipron studies and initial Phase III results for retatrutide in 2025, as these are now critical to justifying the company's growth narrative.
• Evaluate the increasing competitive pressure by tracking key developments, especially the FDA's Q4 decision on Novo Nordisk’s oral Wegovy and clinical progress from Amgen’s MariTide, which could significantly alter market dynamics.
• Given Lilly's premium forward P/E of 25.29 and recent stock underperformance, it is prudent to weigh the potential of rising earnings estimates against the heightened execution risk demonstrated by the orforglipron trial's efficacy miss and high dropout rate.